American Association for Cancer Research

sorry, we can't preview this file

mct-22-0570_figure_s4_supps4.docx (222.65 kB)

Figure S4 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells

Download (222.65 kB)
journal contribution
posted on 2023-08-10, 20:00 authored by Yoji Nagira, Morio Nagira, Ryohei Nagai, Wataru Nogami, Michinari Hirata, Azumi Ueyama, Tetsuya Yoshida, Mai Yoshikawa, Satomi Shinonome, Hiroshi Yoshida, Miya Haruna, Hiroto Miwa, Natsumi Chatani, Naganari Ohkura, Hisashi Wada, Hidekazu Tanaka

Binding profile of the newly created CCR8 antibody



Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating Tregs is, therefore, expected to activate antitumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong antitumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared with anti–PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting.

Usage metrics

    Molecular Cancer Therapeutics





    Ref. manager